Clinical trials: Renal Carcinoma
Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC)
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
This three-arm randomized phase 2 trial will enroll advanced clear cell RCC patients (all IMDC risk groups). Patients will be randomized 2:2:1 to either Arm A (fianlimab/ cemiplimab/ ipilimumab), Arm B (fianlimab/ cemiplimab), or…
- Conditions
- Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
- Trial name
- NCT07188896
- Testing
- Fianlimab, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 120 people
- Sponsor
- Brian Rini
Renal Tumors
A Multicenter Study of RUS NE
This sponsor-initiated, randomized controlled clinical trial aims to demonstrate the clinical efficacy of RUS NE Surgical Navigation System in patients undergoing robotic-assisted partial nephrectomy.
- Trial name
- NCT06868186
- Testing
- RUS NE
- Where
- 4 sites in South Korea
- Volunteers
- 204 people
- Sponsor
- Hutom Corp
Melanoma, Breast Cancer
MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour
The primary objective is to determine the safety and tolerability of the novel compound, MRx0518 in patients with solid tumours at 30 days post-surgery.
- Conditions
- Melanoma, Breast Cancer, Uterine Cancer, Ovarian Cancer
- Trial name
- MICROBIOME (NCT03934827)
- Testing
- MRx0518 Capsules
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Imperial College London
Breast Carcinoma, Colon Carcinoma
Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer
This pilot clinical trial studies how well social media listening works in improving clinical trial recruitment in patients with cancer.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Kidney Carcinoma, Lymphoma
- Trial name
- NCT03408561
- Testing
- Internet-Based Intervention, Survey Administration
- Where
- United States
- Sponsor
- University of Southern California
Renal Cell Carcinoma
Tivozanib + Gemcitabine in Metastatic RCC
This research study is a PHase II clinical trial, which tests the safety and effectiveness of an investigational combination of drugs to learn whether the combination of drugs works in treating a specific cancer.
- Trial name
- NCT01834183
- Testing
- Tivozanib, Gemcitabine
- Where
- 4 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Advanced Clear Cell Renal Cell Carcinoma
A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC
This is a phase I, open-label, single-arm study conducted to evaluate the efficacy, safety and PK of CGC738 in the treatment of advanced clear cell renal cell carcinoma (ccRCC).
- Trial name
- NCT06870279
- Testing
- CGC738
- Volunteers
- 28 people
- Sponsor
- RenJi Hospital
Renal Cancer, Non Small Cell Lung Cancer (NSCLC)
Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
The purpose of this study is to determine if a new investigational drug called Panobinostat is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination with Sorafenib for the treatment of certain…
- Conditions
- Renal Cancer, Non Small Cell Lung Cancer (NSCLC), Soft Tissue Sarcoma
- Trial name
- NCT01005797
- Testing
- Panobinostat (LBH589), Sorafenib
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Medical University of South Carolina
Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
This study is being done to collect tissue samples to test how accurately a tumor response platform, Elephas, can predict clinical response across multiple types of immunotherapies, chemoimmunotherapy and tumor types.
- Conditions
- Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Cervical Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma
- Trial name
- ELEPHAS-04 (NCT06349642)
- Testing
- Biospecimen Collection, Tissue Collection
- Where
- 3 sites in United States
- Volunteers
- 324 people
- Sponsor
- Mayo Clinic
Bladder Cancer
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Gemcitabine and Cisplatin are standard chemotherapy drugs used to treat advanced urothelial cancer. There is no standard chemotherapy for patients who cannot receive Cisplatin.
- Trial name
- NCT01622660
- Testing
- Gemcitabine, Pazopanib
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as thrombopoietin and G-CSF may increase the number of immune cells found in…
- Trial name
- NCT00003597
- Testing
- recombinant human thrombopoietin, carboplatin, etoposide
- Where
- 24 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Children's Oncology Group
Stomach Neoplasms, Colonic Neoplasms
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
Postoperative delirium（POD）is a common complication that can directly affect important clinical outcomes, and exert an enormous burden on patients, their families, hospitals, and public resources.
- Conditions
- Stomach Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Sigmoid Neoplasms
- Trial name
- NCT05068180
- Testing
- low-dose neuroleptanalgesia
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- RenJi Hospital
Renal Carcinoma Metastatic
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma
This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR-TKI and decrease the related toxicity…
- Trial name
- TIDE-A (NCT04698213)
- Testing
- Axitinib Oral Tablet, Avelumab
- Where
- 20 sites in Italy
- Volunteers
- 75 people
- Sponsor
- Consorzio Oncotech
Kidney Neoplasms
Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy
Partial nephrectomy is considered the standard treatment for renal tumors smaller than 7 cm. With the evolution of image diagnostic tools and dissemination of its use, smaller tumors are being commonly diagnosed and treated.
- Trial name
- NCT01809119
- Testing
- Partial nephrectomy
- Where
- Brazil
- Volunteers
- 242 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Renal Cell Cancer
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type) who have had nephrectomy.
- Trial name
- NCT00738530
- Testing
- Bevacizumab [Avastin], Interferon alfa 2a [Roferon]
- Where
- 104 sites in Australia, Belgium and 16 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Adult Primary Liver Cancer, Kidney Tumor
Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions
This clinical trial studies ultrasound elastography in diagnosing patients with kidney or liver solid focal lesions. New diagnostic procedures, such as ultrasound elastography, may be a less invasive way to check for kidney or…
- Trial name
- NCT01908166
- Testing
- ultrasound elasticity imaging
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Stanford University
Cancer, Solid Tumor
Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer.
- Trial name
- NCT00333502
- Testing
- Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- NewLink Genetics Corporation
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Carcinoma, Transitional Cell
Chemoprevention Trial for Uremia-Associated Urothelial Carcinoma
Primary Objective: To study if lycopene can improve the biomarker status of urothelial cells in patients with uremia-associated urothelial carcinoma.
- Trial name
- NCT00172367
- Testing
- Lycopene
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Kidney Neoplasm
Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma
This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) - a minimally invasive procedure to remove a small kidney tumor while preserving…
- Trial name
- K3 (NCT07234409)
- Testing
- STANDARD FLANK APPROACH, Supine anterior retroperitoneal approach (SARA).
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Niguarda Hospital
Kidney Cancer, Renal Cell Carcinoma
Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States
Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries. In particular, rates among African Americans have risen more sharply than any other cancer site.
- Trial name
- NCT00340457
- Where
- 2 sites in United States
- Volunteers
- 2,424 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.